BMRN
BioMarin Pharmaceutical Inc. Healthcare - Biotechnology Investor Relations →
BioMarin Pharmaceutical Inc. (BMRN) closed at $54.69 as of 2026-06-19, trading 28.7% below its 200-week moving average of $76.66. This places BMRN in the extreme value zone. The stock is currently moving closer to the line, down from -27.2% last week. The 14-week RSI sits at 40, indicating neutral momentum.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.92 ratio) is neutral — neither side is clearly dominating.
Over the past 1355 weeks of data, BMRN has crossed below its 200-week moving average 33 times. On average, these episodes lasted 21 weeks. Historically, investors who bought BMRN at the start of these episodes saw an average one-year return of +2.1%.
With a market cap of $10.6 billion, BMRN is a large-cap stock. The company generates a free cash flow yield of 4.3%. Return on equity stands at 4.5%. The stock trades at 1.7x book value.
Share count has increased 3.2% over three years, indicating dilution.
Over the past 26 years, a hypothetical investment of $100 in BMRN would have grown to $304, compared to $829 for the S&P 500. BMRN has returned 4.4% annualized vs 8.5% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 152.8% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BMRN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BMRN Crosses Below the Line?
Across 33 historical episodes, buying BMRN when it crossed below its 200-week moving average produced an average return of +2.0% after 12 months (median +2.0%), compared to +17.2% for the S&P 500 over the same periods. 55% of those episodes were profitable after one year. After 24 months, the average return was +1.4% vs +33.4% for the index.
Each line shows $100 invested at the moment BMRN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BMRN would reach each dislocation threshold.
Dislocation Price Levels
Prices where BMRN's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-08-03.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $50.29 | Unusually cheap — potential buy zone |
| Value | +1σ | $52.20 | Cheap vs. own history |
| Fair Value | +0σ | $54.26 | Historical mean behavior |
| Expensive | -1σ | $56.49 | Expensive vs. own history |
| Deep Expensive | -2σ | $58.92 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BMRN's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BMRN has crossed below its 200-week MA 33 times with an average 1-year return of +2.1% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2000 | Mar 2003 | 139 | 68.6% | -34.2% | +203.8% |
| Apr 2003 | Jul 2005 | 117 | 53.8% | -37.0% | +386.1% |
| Oct 2008 | Jan 2009 | 14 | 19.8% | +0.4% | +222.8% |
| Feb 2009 | Mar 2010 | 55 | 47.0% | +6.4% | +194.7% |
| May 2010 | Sep 2010 | 18 | 14.8% | +28.5% | +176.2% |
| Oct 2010 | Oct 2010 | 1 | 0.2% | +52.4% | +150.1% |
| Jan 2016 | Feb 2016 | 3 | 9.6% | +16.9% | -26.1% |
| Jun 2016 | Jun 2016 | 1 | 4.0% | +23.4% | -29.0% |
| Oct 2016 | Nov 2016 | 3 | 4.1% | +6.6% | -33.5% |
| Nov 2016 | Jan 2017 | 5 | 3.8% | +3.4% | -33.5% |
| Jan 2017 | Jan 2017 | 1 | 2.0% | +5.3% | -35.4% |
| Mar 2017 | Mar 2017 | 1 | 0.1% | -9.8% | -37.4% |
| May 2017 | May 2017 | 1 | 0.9% | +5.1% | -37.9% |
| Jun 2017 | Jun 2017 | 1 | 0.8% | +10.3% | -38.2% |
| Jul 2017 | Sep 2017 | 8 | 10.1% | +14.1% | -38.7% |
| Oct 2017 | Jun 2018 | 34 | 18.5% | +17.6% | -37.7% |
| Jun 2018 | Jul 2018 | 1 | 0.6% | -9.1% | -41.9% |
| Nov 2018 | Jan 2020 | 61 | 25.5% | -20.7% | -42.8% |
| Jan 2020 | Feb 2020 | 3 | 5.1% | +2.1% | -36.5% |
| Mar 2020 | Apr 2020 | 5 | 17.0% | -9.1% | -35.3% |
| Aug 2020 | Nov 2021 | 65 | 19.4% | +0.1% | -27.1% |
| Nov 2021 | Dec 2021 | 3 | 4.4% | +27.3% | -34.1% |
| Jan 2022 | Jan 2022 | 4 | 3.0% | +29.0% | -35.1% |
| Feb 2022 | Jul 2022 | 20 | 12.6% | +27.6% | -35.6% |
| Jul 2022 | Jul 2022 | 1 | 0.2% | +2.9% | -35.8% |
| Sep 2022 | Oct 2022 | 2 | 0.3% | +2.0% | -35.5% |
| Oct 2022 | Nov 2022 | 2 | 3.3% | -3.5% | -33.7% |
| Jun 2023 | Jul 2023 | 3 | 2.5% | -5.0% | -36.9% |
| Sep 2023 | Nov 2023 | 9 | 9.8% | -18.3% | -36.8% |
| Jan 2024 | Feb 2024 | 2 | 0.5% | -28.1% | -37.9% |
| Feb 2024 | Apr 2024 | 6 | 5.2% | -18.3% | -37.2% |
| Apr 2024 | Aug 2024 | 15 | 13.3% | -21.8% | -32.4% |
| Sep 2024 | Ongoing | 94+ | 36.5% | Ongoing | -35.0% |
| Average | 21 | — | +2.1% | — |
Frequently Asked Questions
Is BMRN below its 200-week moving average?
Yes. As of 2026-06-19, BioMarin Pharmaceutical Inc. (BMRN) is trading 28.7% below its 200-week moving average of $76.66. The current price is $54.69.
What is BMRN's 200-week moving average price?
BioMarin Pharmaceutical Inc.'s 200-week moving average is $76.66 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BMRN drops below its 200-week moving average?
BMRN has crossed below its 200-week moving average 33 times in our data. On average, buying at that moment produced a one-year return of +2.1%. These dips have historically been decent entry points. These episodes lasted 21 weeks on average.
Is BMRN a good value right now?
Here's what our data says about BMRN as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 40. Free cash flow yield is 4.3%. Return on equity is 4.5%. Price-to-book is 1.7x. This is not a buy or sell recommendation — always do your own research.
How does BMRN compare to the S&P 500?
Over the past 26 years, $100 invested in BMRN would have grown to $304, compared to $829 for the S&P 500. That's 4.4% annualized vs 8.5% for the index. BMRN has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19